You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Single-session bronchial thermoplasty for severe asthmatics guided by HXe MRI

    SBC: XEMED LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Roughly one million Americans with inadequately controlled severe persistent asthma have a particularly high risk of exacerbations hospitalizations and death and account for a per patient health care burden exceeding $ annually Bronchial thermoplasty BT applies radiofrequency heating to airway smooth muscle reducing its thickness and hyper reactivity This novel mi ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. High-specificity affinity reagents for N-glycosylation site mapping and glycomics

    SBC: GLYCOSENSORS AND DIAGNOSTICS, LLC            Topic: 300

    DESCRIPTION Glycans have several distinct properties that make them excellent targets for disease biomarkers Firstly the location of the glycans on the cell surface makes them the first point of contact of cellular interactions and thus crucial in the control of normal metabolic processes Cell surface molecules are also strategically exposed for surveillance by the immune system allowing for ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Stimulating Young Neuroscientists And Physiologists in Science Education- Phase

    SBC: IS3D LLC            Topic: 101

    DESCRIPTION provided by applicant This project will develop a suite of innovative learning experiences that will engage high school students in neuroscience and thereby increase their interest in possible careers in this area This will be achieved by creating highly interactive and immersive products developed in partnership with neuroscience experts science teachers and science education re ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. An Automated Platform for High-throughput Network Electrophysiology

    SBC: Axion Biosystems, Inc.            Topic: 102

    DESCRIPTION provided by applicant In response to the program announcement for Phase IIb proposals for complex in vitro brain and behavior tools PA this proposed study automates all aspects of in vitro Microelectrode Array MEA technology to deliver the first ever high throughput MEA based screening system This development will not only enable rapid advancements in the study of basi ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Safe and effective anti CD154 antibodies for therapeutic intervention

    SBC: Immunext, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant In both animal proof of concept studies and preliminary clinical trials there is ample data demonstrating the potential therapeutic benefits o CD blockade for treatment of GVHD organ transplantation and autoimmune diseases However development of CD as a therapeutic has been impeded by antibody toxicity observed in early clinical trials GVHD is a ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Safe And Effective Anti-CD154 Antibodies For Therapeutic Intervention

    SBC: Immunext, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): There is compelling evidence that ?CD154 treatment has great potential in autoimmunity and graft rejection. Autoimmunity. Clinical efficacy of ?CD154 treatment has been seen in Lupus and idiopathic thrombocytopenia. In addition, Principal Investigator Dr. Noelle's clinical experience with ?CD154 is based on a Phase I trial in remitting/ relapsi ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government